Previous 10 | Next 10 |
Shares of Prometheus Biosciences ( NASDAQ: RXDX ) rose as much as 11.3% to $34.23 in Wednesday trading after Goldman Sachs initiated the company with a buy rating. Goldman Sachs analyst Chris Shibutani gave RXDX stock a price target of $51, implying a 65.8% upside to RXD...
- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 - - PRA052 is a novel, first-in-class monoclonal antibody addressing a target with one of the stro...
- G lobal Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies - - Enrollment initiated in Cohort 2 of CDx+ patients to evaluate the company’s companion diagnostic - - Both APOLLO-CD an...
- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn’s disease patients - - ARTEMIS-UC Phase 2 Cohort 1 enrollment on track with completion expected 3Q 2022 - - Both APOLLO-CD and ARTEMIS-UC topline results expected 4Q 2022 ȁ...
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the ...
Prometheus Biosciences press release (NASDAQ:RXDX): Q1 GAAP EPS of -$0.82. Collaboration revenue of $3.92M. For further details see: Prometheus Biosciences GAAP EPS of -$0.82, revenue of $3.92M
- Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - - Announced key appointments in Leadership Team - - Strong cash positio...
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has granted Fast Track Designation for PRA023 for the treatment of SSc-ILD - ...
- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn’s disease expected in fourth quarter 2022 - - Phase 2 trial in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) on track to initiate this quarter - ...
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for th...
News, Short Squeeze, Breakout and More Instantly...
Prometheus Biosciences Inc. Company Name:
RXDX Stock Symbol:
NASDAQ Market:
Prometheus Biosciences Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 25, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Prometheus Biosciences, Inc. (NASDAQ:RXDX...
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated disease...